Literature DB >> 10775593

Expression of an antigenic adenovirus epitope in a group B coxsackievirus.

K Höfling1, S Tracy, N Chapman, K S Kim, J Smith Leser.   

Abstract

Group B coxsackieviruses (CVB) cause human myocarditis, while human adenovirus type 2 (Ad2) is implicated as an agent of this disease. The L1 loop of the Ad2 hexon protein has been demonstrated to be antigenic in rabbits. To evaluate the feasibility of a multivalent vaccine strain against the CVB and Ad2, we cloned the sequence encoding the Ad2 hexon L1 loop, flanked by dissimilar sequences encoding the protease 2A (2Apro) recognition sites, into the genome of an attenuated strain of CVB type 3 (CVB3/0) at the junction of 2Apro and the capsid protein 1D. Progeny virus (CVB3-PL2-Ad2L1) was obtained following transfection of the construct into HeLa cells. Replication of CVB3-PL2-Ad2L1 in diverse cell cultures demonstrated that the yield of the chimeric virus was between 0.5 to 2 log units less than the parental strain. Western blot analyses of the CVB3 capsid protein 1D in CVB3-PL2-Ad2L1-infected HeLa cells demonstrated production of the expected capsid protein. Viral proteins were detected earlier and in approximately fourfold greater amounts in CVB3-PL2-Ad2L1-infected HeLa cells than in CVB3/0-infected cells. Cleavage of the CVB3-PL2-Ad2L1 polyprotein by 2Apro was slowed, accompanied by an accumulation of the fusion 1D-L1 loop protein. Reverse transcription-PCR sequence analysis of CVB3-PL2-Ad2L1 RNA demonstrated that the Ad2 hexon polypeptide coding sequence was maintained in the chimeric viral genome through at least 10 passages in HeLa cells. Mice inoculated with CVB3-PL2-Ad2L1 demonstrated a brief viremia with no replication detectable in the heart but prolonged replication of virus in the pancreas in the absence of pathologic changes in either organ. CVB3-PL2-Ad2L1 induced binding and neutralizing anti-Ad2 antibodies, in addition to antibodies against CVB3 in mice. CVB3-PL2-Ad2L1 was used to challenge mice previously inoculated with CVB3/0 and with preexisting anti-CVB3 neutralizing-antibody titers; anti-Ad2 neutralizing and binding antibodies were induced in these mice at higher levels than in mice without anti-CVB3 immunity. The data demonstrate that a CVB vector can stably express an antigenic polypeptide of Ad2 from within the CVB open reading frame that results in the induction of protective immune responses against both viruses.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10775593      PMCID: PMC111977          DOI: 10.1128/jvi.74.10.4570-4578.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  62 in total

1.  Tissue-specific consequences of the anti-adenoviral immune response: implications for cardiac transplants.

Authors:  S Y Chan; K Li; J R Piccotti; M C Louie; T A Judge; L A Turka; E J Eichwald; D K Bishop
Journal:  Nat Med       Date:  1999-10       Impact factor: 53.440

2.  Antipeptide antisera define neutralizing epitopes on the adenovirus hexon.

Authors:  C I Toogood; J Crompton; R T Hay
Journal:  J Gen Virol       Date:  1992-06       Impact factor: 3.891

Review 3.  The biologic principles of poliovirus eradication.

Authors:  W R Dowdle; M E Birmingham
Journal:  J Infect Dis       Date:  1997-02       Impact factor: 5.226

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

Review 5.  Autoimmunity in myocarditis: relevance of animal models.

Authors:  S A Huber
Journal:  Clin Immunol Immunopathol       Date:  1997-05

Review 6.  Viral myocarditis. A review.

Authors:  J F Woodruff
Journal:  Am J Pathol       Date:  1980-11       Impact factor: 4.307

7.  Generation of an infectious cDNA of a highly cardiovirulent coxsackievirus B3(CVB3m) and comparison to other infectious CVB3 cDNAs.

Authors:  C Lee; E Maull; N Chapman; S Tracy; J Wood; C Gauntt
Journal:  Virus Res       Date:  1997-08       Impact factor: 3.303

8.  Mucosal immunization of cynomolgus macaques with two serotypes of live poliovirus vectors expressing simian immunodeficiency virus antigens: stimulation of humoral, mucosal, and cellular immunity.

Authors:  S Crotty; B L Lohman; F X Lü; S Tang; C J Miller; R Andino
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

9.  Acute myocarditis. Rapid diagnosis by PCR in children.

Authors:  A B Martin; S Webber; F J Fricker; R Jaffe; G Demmler; D Kearney; Y H Zhang; J Bodurtha; B Gelb; J Ni
Journal:  Circulation       Date:  1994-07       Impact factor: 29.690

10.  Poliovirus vaccine vectors elicit antigen-specific cytotoxic T cells and protect mice against lethal challenge with malignant melanoma cells expressing a model antigen.

Authors:  S Mandl; L J Sigal; K L Rock; R Andino
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-07       Impact factor: 11.205

View more
  15 in total

1.  Coxsackievirus expression of the murine secretory protein interleukin-4 induces increased synthesis of immunoglobulin G1 in mice.

Authors:  N M Chapman; K S Kim; S Tracy; J Jackson; K Höfling; J S Leser; J Malone; P Kolbeck
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

2.  A novel pancreatropic coxsackievirus vector expressing glucagon-like peptide 1 reduces hyperglycemia in streptozotocin-treated mice.

Authors:  Meixia Dan; Janet K Chantler
Journal:  J Virol       Date:  2011-09-21       Impact factor: 5.103

3.  Analysis of translational initiation in coxsackievirus B3 suggests an alternative explanation for the high frequency of R+4 in the eukaryotic consensus motif.

Authors:  Stephanie Harkins; Christopher T Cornell; J Lindsay Whitton
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

4.  Toward testing the hypothesis that group B coxsackieviruses (CVB) trigger insulin-dependent diabetes: inoculating nonobese diabetic mice with CVB markedly lowers diabetes incidence.

Authors:  S Tracy; K M Drescher; N M Chapman; K-S Kim; S D Carson; S Pirruccello; P H Lane; J R Romero; J S Leser
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

Review 5.  Multivalent and Multipathogen Viral Vector Vaccines.

Authors:  Katharina B Lauer; Ray Borrow; Thomas J Blanchard
Journal:  Clin Vaccine Immunol       Date:  2017-01-05

6.  Using recombinant coxsackievirus B3 to evaluate the induction and protective efficacy of CD8+ T cells during picornavirus infection.

Authors:  M K Slifka; R Pagarigan; I Mena; R Feuer; J L Whitton
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

7.  Protection against simian immunodeficiency virus vaginal challenge by using Sabin poliovirus vectors.

Authors:  S Crotty; C J Miller; B L Lohman; M R Neagu; L Compton; D Lu; F X Lü; L Fritts; J D Lifson; R Andino
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

8.  Expression of immunoregulatory cytokines by recombinant coxsackievirus B3 variants confers protection against virus-caused myocarditis.

Authors:  A Henke; R Zell; G Ehrlich; A Stelzner
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

9.  5'-Terminal deletions occur in coxsackievirus B3 during replication in murine hearts and cardiac myocyte cultures and correlate with encapsidation of negative-strand viral RNA.

Authors:  K-S Kim; S Tracy; W Tapprich; J Bailey; C-K Lee; K Kim; W H Barry; N M Chapman
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

10.  Cell cycle status affects coxsackievirus replication, persistence, and reactivation in vitro.

Authors:  Ralph Feuer; Ignacio Mena; Robb Pagarigan; Mark K Slifka; J Lindsay Whitton
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.